Remimazolam: First Approval

被引：163

作者：

Keam, Susan J. ^{[1
]}

机构：

[1] Springer Nat, Private Bag 65901,Mairangi Bay, Auckland 0754, New Zealand

来源：

DRUGS | 2020年 / 80卷 / 06期

关键词：

CNS; 7056; MIDAZOLAM; SAFETY; EFFICACY; PLACEBO; PHARMACODYNAMICS; PHARMACOKINETICS; SEDATION;

D O I：

10.1007/s40265-020-01299-8

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Remimazolam (Anerem(R) in Japan; ByFavo (TM) in the USA; Aptimyda (TM) in the EU) is an ultra-short-acting intravenous (IV) benzodiazepine sedative/anesthetic being developed by PAION AG in conjunction with a number of commercial partners for use in anesthesia and procedural sedation. Remimazolam was approved on 23 January 2020 in Japan for use in general anesthesia in adult patients. Remimazolam is also undergoing regulatory assessment in South Korea for this indication and for use in procedural sedation in the USA, the EU and China. This article summarises the major milestones in the development of remimazolam for this first approval for the induction and maintenance of general anaesthesia, and its potential upcoming approvals in general anaesthesia and procedural sedation.

引用

页码：625 / 633

页数：9

共 25 条

[1] A Placebo- and Midazolam-Controlled Phase I Single Ascending-Dose Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of Remimazolam (CNS 7056): Part I. Safety, Efficacy, and Basic Pharmacokinetics [J].

Antonik, Laurie J. ;

Goldwater, D. Ronald ;

Kilpatrick, Gavin J. ;

Tilbrook, Gary S. ;

Borkett, Keith M. .

ANESTHESIA AND ANALGESIA, 2012, 115 (02) :274-283

[2] Inhaled Remimazolam Potentiates Inhaled Remifentanil in Rodents [J].

Bevans, Tatjana ;

Deering-Rice, Cassandra ;

Stockmann, Chris ;

Rower, Joseph ;

Sakata, Derek ;

Reilly, Christopher .

ANESTHESIA AND ANALGESIA, 2017, 124 (05) :1484-1490

[3] A Phase IIa, Randomized, Double-Blind Study of Remimazolam (CNS 7056) Versus Midazolam for Sedation in Upper Gastrointestinal Endoscopy [J].

Borkett, Keith M. ;

Riff, Dennis S. ;

Schwartz, Howard I. ;

Winkle, Peter J. ;

Pambianco, Daniel J. ;

Lees, James P. ;

Wilhelm-Ogunbiyi, Karin .

ANESTHESIA AND ANALGESIA, 2015, 120 (04) :771-780

[4]

ClinicalTrials.gov, 2015, SAF EFF REM ASA 3 4

[5] Pharmacokinetics and Pharmacodynamics of Remimazolam (CNS 7056) after Continuous Infusion in Healthy Male Volunteers Part II. Pharmacodynamics of Electroencephalogram Effects [J].

Eisenried, Andreas ;

Schuettler, Juergen ;

Lerch, Marco ;

Ihmsen, Harald ;

Jeleazcov, Christian .

ANESTHESIOLOGY, 2020, 132 (04) :652-666

[6]

EU Clinical Trials Register, 2016, RAND SINGL BLIND PHA

[7] Metabolism of remimazolam in primary human hepatocytes during continuous long-term infusion in a 3-D bioreactor system [J].

Freyer, Nora ;

Knoespel, Fanny ;

Damm, Georg ;

Greuel, Selina ;

Schneider, Christin ;

Seehofer, Daniel ;

Stoehr, Thomas ;

Petersen, Karl-Uwe ;

Zeilinger, Katrin .

DRUG DESIGN DEVELOPMENT AND THERAPY, 2019, 13 :1033-1047

[8]

Google Patents, 2020, DOS REG SED CNS 7056

[9]

Hill N, 2019, AM J RESP CRIT CARE, V199

[10] CNS 7056 - A novel ultra-short-acting benzodiazepine [J].

Kilpatrick, Gavin J. ;

McIntyre, Margaret S. ;

Cox, Richard F. ;

Stafford, Jeffrey A. ;

Pacofsky, Gregory J. ;

Lovell, Gwyer G. ;

Wiard, Robert P. ;

Feldman, Paul L. ;

Collins, Holly ;

Waszczak, Barbara L. ;

Tilbrook, Gary S. .

ANESTHESIOLOGY, 2007, 107 (01) :60-66

← 1 2 3 →